Covidien reveals that it is under federal subpoena

In its annual 10-K filing with the SEC, Covidien ($COV) quietly noted that it is under a federal subpoena related to some of its peripheral vascular products. "On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General, issued a subpoena requesting production of documents relating to certain of our peripheral vascular products. We are complying as required with the terms of the subpoena," the filing states. Filing

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.